BioCentury
ARTICLE | Clinical News

AMD3100: Began Phase I testing

March 26, 2001 8:00 AM UTC

AnorMed Inc. (TSE:AOM), Langley, B.C. Product: AMD3100 Business: Infectious diseases Therapeutic category: Viral infection Target: CXCR4 chemokine receptors Description: Synthetic CXCR4 receptor ant...